Tumor peptide vaccines mainly based on HLA-restricted antigen epitope which could induce both CD4+ and CD8+ immune response against specific tumor-associated antigens (TAA) or tumor-specific antigens (TSA) which highly expressed in cancer cells and not in normal tissues (82). Here, CD8A is linked to neoplasm.